
    
      This is a study in humans of ELX-02, an advanced synthetic aminoglycoside optimized as a
      translational read-through drug (TRID) for the treatment of genetic conditions caused by
      nonsense mutations. This is a classical Phase 1a study designed as a randomized,
      double-blinded, placebo-controlled, single dose escalation to evaluate the safety,
      tolerability and pharmacokinetics of ELX-02 in healthy adult volunteers.
    
  